S011806 is an oral small molecule antagonist of IL-17 developed for the treatment of psoriasis and has entered the phase I clinical stage to explore its safety and pharmacokinetic characteristics, but preclinical data have not yet been disclosed. The gene discussed is IL17A; the disease is psoriasis.